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Use of the Epidermal Growth Factor Receptor Inhibitors
Gefitinib and Erlotinib in the Treatment of Non-small Cell
Lung Cancer: A Systematic Review
Ron Feld, MD,* Srikala S. Sridhar, MD, MSc,† Frances A. Shepherd, MD,* Jean A. Mackay, MA,‡
William K. Evans, MD,† and the Lung Cancer Disease Site Group of Cancer Care
Ontario’s Program in Evidence-based Care§
Introduction: Inhibition of the epidermal growth factor receptor is
a promising therapy in the treatment of non-small cell lung cancer
(NSCLC). In this systematic review, we evaluated the role of the
epidermal growth factor receptor inhibitors gefitinib and erlotinib in
the treatment of patients with advanced NSCLC.
Methods: Relevant randomized trials published as articles or ab-
stracts were identified through a systematic search of the literature
from 1975 to November 2005 by two independent reviewers.
Results: Twelve randomized trials met the predefined eligibility
criteria for this systematic review. Four large placebo-controlled
trials demonstrated that the addition of gefitinib or erlotinib to
platinum-based first-line chemotherapy did not significantly im-
prove overall survival or time-to-disease progression. A large pla-
cebo-controlled trial revealed a clinically and statistically significant
survival benefit for erlotinib therapy as second- or third-line sys-
temic therapy. The results of a single placebo-controlled trial and
two phase II trials suggest that modest tumor response rates and
symptom control can be achieved with gefitinib as second-line or
subsequent therapy; however, a statistically significant survival
benefit was not found for gefitinib compared with placebo.
Conclusion: There is strong evidence to recommend against the use
of gefitinib or erlotinib in combination with chemotherapy or as
maintenance therapy after chemotherapy and radiation as a first-line
treatment for advanced NSCLC. Erlotinib monotherapy is an effec-
tive treatment that can prolong survival for patients with advanced
NSCLC whose disease has relapsed or recurred after prior chemo-
therapy. Although a significant survival benefit has not been dem-
onstrated for gefitinib in a placebo-controlled study, the two ran-
domized phase II trials suggest that gefitinib may provide clinically
important symptomatic benefits.
Key Words: Non-small cell lung cancer, Gefitinib, Erlotinib, Sys-
tematic review.
(J Thorac Oncol. 2006;1: 367–376)
Globally, lung cancer is the leading cause of cancer deathsamong men and the second leading cause among wom-
en.1 Non-small cell histology accounts for 70% to 80% of
lung cancer cases2 and is generally diagnosed at an advanced
stage. Surgery is the primary treatment for early-stage dis-
ease, with an approximate 5-year survival range of between
35% (stage II) and 70% (completely resected stage I).3 For
advanced disease (stages IIIB and IV), 5-year survival is
typically less than 5%,2 and median survival for patients
treated with platinum-based chemotherapy is in the range of
8 to 10 months. The long-term survival of patients with
advanced non-small cell lung cancer (NSCLC) remains poor,
and additional treatment options continue to be explored.
The most promising chemotherapeutic agents for pa-
tients with relapsed or recurrent advanced NSCLC after
first-line therapy are docetaxel (75 mg/m2)4 and pemetrexed
(500 mg/m2 supplemented with vitamin B12 and folic acid).5
In one randomized trial, median survival was significantly
prolonged with second-line docetaxel (7.5 months) compared
with best supportive care (BSC; 4.6 months),6 and, in a recent
randomized trial, median survival was 8.3 months for pem-
etrexed compared with 7.9 months for docetaxel when used
as second-line chemotherapy.5
One approach to improving survival in NSCLC is to
consider the use of targeted therapies. The family of epider-
mal growth factor tyrosine kinase receptors, including epi-
dermal growth factor receptors (EGFR) (Erb1 or HER1),
HER2 (Erb2 or Neu), HER3 (Erb3), and HER4 (Erb4) seems
to be an important target in NSCLC.7 Functional changes and
dysregulation of these tyrosine kinase receptors, particularly
EGFR, have been associated with features common to cancer
cells, including autonomous growth, local invasion, and met-
astatic spread.7 Because the EGFR family of receptors is
expressed in many NSCLC tumors and other common ma-
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lignancies, this family of receptors has been the subject of
active drug development in recent years, with many novel
agents now targeting these receptors.
The EGFR inhibitors gefitinib and erlotinib have shown
promising results in the treatment of NSCLC. In light of these
developments, we conducted a systematic review to evaluate
the evidence for this new therapy, to assist clinicians in
making appropriate decisions regarding this therapy, and to
promote evidence-based practice. In this systematic review,
we address the role of the EGFR inhibitors gefitinib and
erlotinib in the treatment of patients with advanced NSCLC.
METHODS
This systematic review was developed by Cancer Care
Ontario’s Program in Evidence-based Care (PEBC) and
forms the basis for a practice guideline. Practice guidelines
developed through the Program follow the methods of the
Practice Guidelines Development Cycle8 and are available on
the Internet at: www.cancercare.on.ca.
Literature Search Strategy
MEDLINE (1996 through November 2005), EMBASE
(1996 through 2005, week 47), CANCERLIT (1975 through
October 2002), and the Cochrane Library (2005, Issue 4)
databases were searched. The subject headings carcinoma,
non-small-cell lung; lung neoplasms; lung non small cell
cancer; lung carcinogenesis; lung adenocarcinoma; lung al-
veolus cell carcinoma; lung squamous cell carcinoma; erlo-
tinib; gefitinib; and epidermal growth factor receptor were
combined with each of the following phrases used as text
words: non small cell lung; Iressa; gefitinib; ZD1839;
Tarceva; erlotinib; OSI774; and EGFR-TK. These terms were
then combined with the search terms for the following pub-
lication types and study designs: practice guidelines, system-
atic reviews, meta-analyses, randomized controlled trials,
clinical trials, phase II clinical trials, phase III clinical trials,
and cohort analyses.
In addition, conference proceedings of the American
Society of Clinical Oncology (ASCO) (1999–2005), the
European Cancer Conference (1999–2003), the International
Association for the Study of Lung Cancer (2003–2005), and
the European Society for Medical Oncology (1999–2004)
were searched for abstracts of relevant trials. The Canadian
Medical Association Infobase (http://mdm.ca/cpgsnew/cpgs/
index.asp) and the National Guidelines Clearinghouse (http://
www.guideline.gov/index.asp) were also searched for exist-
ing evidence-based practice guidelines.
Relevant articles and abstracts were selected and re-
viewed by two reviewers, and the reference lists from those
sources were searched for additional trials, as were the
reference lists from relevant review articles.
Study Selection Criteria
Articles were included in this systematic review if they
were fully published articles or published abstracts of ran-
domized controlled trials (phase II or phase III) comparing
gefitinib or erlotinib, alone or in combination with chemo-
therapy, with placebo, BSC, or chemotherapy, or comparing
different doses or schedules of gefitinib or erlotinib. Data on
symptom control, quality of life (QOL), tumor response rate,
or survival by treatment group had to be reported. Trials
published in a language other than English were not consid-
ered.
RESULTS
Literature Search Results
Twelve randomized trials met the eligibility criteria for
this systematic review. Of those, seven were fully published
articles,9–18 and five were in abstract only.19–26 Data from
slide presentations associated with abstract trial reports were
also included if the presentations were publicly available on
meeting Websites. No relevant systematic reviews or evi-
dence-based clinical practice guidelines were identified.
Outcomes
Gefitinib
Four randomized phase III trials9,10,18,25,26 and five
randomized phase II trials11,13,19–23 have used gefitinib as
treatment for advanced, recurrent, or relapsed NSCLC. Limited
data were available to assess the quality of four of the trials
reported only in abstracts or slide presentations.19–23,25,26
Of the five fully published trials, all were described as
double-blind with a primary outcome of survival, response
rate, or symptom improvement rate.9–13,18 The phase III trials
performed intent-to-treat survival analyses, and, of the two
phase II randomized trials, one reported that more than 99%
of enrolled patients were included in the survival analysis.11
Each of the phase III trials involved an independent data
monitoring committee that oversaw the conduct of the trial
reviewed the interim efficacy analyses and monitored safety
data.9,10,18 Six trials were sponsored by or reported an asso-
ciation with a pharmaceutical company.9–13,18,22,23
First-Line Treatment
Two randomized phase III trials evaluated the addition
of gefitinib to platinum-based chemotherapy.9,10 One ran-
domized phase III trial evaluated the use of gefitinib as
maintenance therapy after concurrent chemoradiation fol-
lowed by consolidation therapy.25,26 In addition, one small
randomized phase II trial compared gefitinib combined with
gemcitabine or vinorelbine.19 Preliminary results of this trial
were reported at ASCO 2004 and are not discussed in detail
in this review.
Gefitinib Combined with Platinum-Based Chemotherapy
Two international, multicenter, phase III trials (Iressa
NSCLC Trial Assessing Combination Treatment; INTACT 1
and 2)9,10 each randomized more than 1,000 patients to a
standard intravenous chemotherapy regimen (gemcitabine
with cisplatin in INTACT 1 and paclitaxel with carboplatin in
INTACT 2) combined with placebo or oral gefitinib in a dose
of either 250 mg per day or 500 mg per day. Either gefitinib
or placebo was administered until disease progression. In
each trial, approximately 90% of the randomized patients
exhibited a good performance status (PS; 0–1), most had
stage IV disease (69% to 80%), between 46%9 and 55%10 had
adenocarcinomas; and the treatment groups were comparable
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TABLE 1. Randomized trials of gefitinib
Study Participants na Regimen
Response
rate (%)
Survival
QOL/symptom
control
Median
(mo)
Overall
(%)
First-line treatment 1 yr
Giaccone et al.9 No prior CT, stage III or
IV NSCLC not curable
by surgery or
radiotherapy, PS 0-2,
stable brain metastases
allowed
363
365
365
CTb placebo
CTb  gefitinib 250 mg/d
CTb  gefitinib 500 mg/d
47.2
51.2
50.3
10.9
9.9
9.9
44
41
43
Time to worsening
of symptoms not
significantly
different among
groups
p  NS p  0.456 log rank
1 yr
Herbst et al.10 No prior CT, inoperable
stage III or IV NSCLC,
PS 0-2, previously
treated stable brain
metastases allowed
345
345
347
CTc  placebo,
CTc  gefitinib 250 mg/d
CTc  gefitinib 500 mg/d
28.7
30.4
30.0
9.9
9.8
8.7
42
41
37
Time to worsening
of symptoms not
significantly
different among
groupsp  NS p  0.6385 log rank
6 mo
Scagliotti et al.19 No prior CT, stage IIIB or
IV NSCLC, age 70 yr
24d
35d
gefitinib 250 mg/d 
vinorelbine
gefitinib 250 mg/d 
gemcitabine
17
9
12.2
9.0
63
61
NR
Kelly et al.25,26 No prior CT, inoperable
stage III NSCLC, PS
0-1
124
131
CTRT-CTe  gefitinib
(250 mg/d or 500 mg/d)
as maintenance therapy
CT RT- CTe 
placebo
NR 19
29
NR NR
p  0.09 log rank
Second-line or later treatment 1 year
Thatcher et al.18 1-2 prior CT regimens,
refractory or intolerant
to latest CT regimen,
locally advanced or
metastatic NSCLC
1129d
563d
gefitinib 250 mg/d
placebo
8.0
1.3
p  0.0001
5.6
5.1
p  0.087
27
21
QOL improvement
rate on LCS,
25.5% and 17.9%
(p  0.068)
Symptom
improvement
greater with
gefitinib
(p  0.019)
HR 0.89 (95% CI, 0.77-1.02)
Cufer et al.20,21 Stage IIIB/IV NSCLC, PS
0-2, progressed on or
after previous CT
68
73
gefitinib 250 mg/d
docetaxel 75 mg/m2
13.2
13.7
7.5
7.1
NR QOL improvement
rate on LCS,
33.8% vs. 26.0%
Symptom
improvement rate
on LCS, 36.8%
vs. 26.0%
p  0.88
HR 0.97 (95% CI, 0.61-1.52)
1 year
Fukuoka et al.11 1-2 prior CT regimens, at
least 1 platinum-based,
stage III or IV NSCLC
not curable by surgery
or RT, PS 0-2
103
106
gefitinib 250 mg/d
gefitinib 500 mg/d
18.4
19.0
p  NS
7.6
8.0
35
29
Symptom response
40.3%
patients
37.0% patients
140 patients
evaluable on LCS
Projected
1 year
Kris et al.12 2 or more prior CT
regimens containing
platinum and docetaxel,
stage IIIB or IV
NSCLC, PS 0-2,
symptomatic (LCS
FACT-L score 24)
102
114
gefitinib 250 mg/d
gefitinib 500 mg/d
12
9
p  0.51
7
6
p  0.40
27
24
p  0.54
Symptom response
43% patients
35% patients
p  0.26
Robinet
et al.22,23
Failed 1st-line platinum-
based CT, stage IIIB or
IV NSCLC, PS 0-2
31
29
gefitinib 250 mg/d 
docetaxel 75 mg/m2
docetaxel 75 mg/m2
19
10.5
NR NR NR
CI, confidence interval; CT, chemotherapy; FACT–L, Functional Assessment of Cancer Therapy–Lung cancer; HR, hazard ratio; LCS, Lung Cancer Subscale; Mo, months; NS,
not statistically significant; NSCLC, non-small cell lung cancer; NR, not reported; PS, performance status; QOL, Quality of Life; RT, radiotherapy. a Number of patients analyzed.
b CT, gemcitabine  cisplatin. c CT, paclitaxel  carboplatin. d Number of patients enrolled. e CT RT - CT: cisplatin and etoposide concurrent with thoracic RT, followed by
consolidation docetaxel.
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with respect to pretreatment characteristics. In both trials, the
dose intensity of standard chemotherapy was comparable
among the three treatment arms; however, the 500 mg dose of
gefitinib was associated with a shorter median time of ad-
ministration, more frequent dose interruptions, and more
frequent dose reductions than the 250 mg dose of gefitinib or
placebo, which had similar results.
Survival and Tumor Response
With a minimal follow-up of 12 months, overall sur-
vival and objective response were not significantly different
among treatment groups in either trial (Table 1).9,10 Similarly,
no statistically significant differences were reported for me-
dian time–to-disease progression (INTACT 1: 5.5 versus 5.8
versus 6.0 months, p  0.7633 log rank; INTACT 2: 4.6
versus 5.3 versus 5.0 months, p 0.0562 log rank for the 500
mg, 250 mg, and placebo treatment groups, respectively). In
both trials, post hoc multivariate analyses that included treat-
ment group and eight pre-specified, pretreatment prognostic
factors suggested that the following were significantly asso-
ciated with poorer survival (p  0.05): a PS of 2, weight loss
5% in the previous 6 months, or the presence of bone or
liver metastases. However, disease stage, gender, tumor his-
tology, and the presence of brain metastases were not asso-
ciated with a better or worse survival outcome.
Symptom Control
The time to worsening of disease-related symptoms,
assessed using the Lung Cancer Subscale (LCS) of the
Functional Assessment of Cancer Therapy–Lung (FACT-L)
questionnaire, was reported in abstract reports of both IN-
TACT 127 and INTACT 228 and was not significantly differ-
ent among treatment arms.
Toxicity
With the exception of diarrhea and skin disorders,
which were dose-dependent, most adverse events classified as
treatment-related were mild and occurred at similar rates
among the three treatment arms in each trial.9,10 Other grade
1 to 4 toxicities occurring in both trials were likely chemo-
therapy-related and included nausea (15% to 19%), vomiting
(9% to 17%), asthenia (10% to 14%), anorexia (6% to 12%),
anemia (3% to 7%), neutropenia (5% to 8%), leukopenia (2%
to 5%), and conjunctivitis (1% to 6%). Thrombocytopenia
TABLE 2. Randomized trials of erlotinib
Study Participants na Regimen Response rate
Survival
QOL/symptom
control
Median
(mo)
Overall
(%)
First-line treatment
Gatzemeier et
al.24
No prior CT, unresectable
stage III or IV NSCLC,
PS 0-1
1172
totald
CTb  placebo
CTb  erlotinib 150 mg/d
NR 10.2
9.9
p  NS
NR Time to symptom
progression not
significantly
different between
groups1 year
Herbst et al.14,15 No prior CT, stage IIIB or
IV NSCLC, PS 0-1
533
526d
CTc  placebo
CTc  erlotinib 150 mg/d
19.3
21.5
p  0.36
10.5
10.6
p  0.95
44
47
NR
HR 0.99 (95% CI, 0.86-1.16)
Second-line or later treatment 1 year
Shepherd et
al.16,17,32
1-2 prior CT regimens
with at least 1
combination CT if age
70 years, stage IIIB or
IV NSCLC, PS 0-3, age
18, symptomatic brain
metastases excluded
488
243
erlotinib 150 mg/d
placebo
8.9
1
p  0.001
6.7
4.7
31
22
Time to symptom
deterioration
longer with
erlotinib:cough,
4.9 vs. 3.7 mo,
p  0.04; dyspnea,
4.7 vs. 2.9 mo, p 
0.03; pain, 2.8 vs.
1.9 mo, p  0.04.
Greater improvement
with erlotinib on
some QOL
measures: global
QOL (p  0.01),
pain (p  0.01),
dyspnea (p 
0.03), cough
(p  0.01), overall
emotional (p 
0.01) and overall
physical (p 
0.01).
HR 0.70 (95% CI, 0.58-0.85)
CI, confidence interval; CT, chemotherapy; HR, hazard ratio; Mo, months; NS, not statistically significant; NSCLC, non-small cell lung cancer; NR, not reported; PS, performance
status; QOL, quality of life. a Number of patients analyzed. b CT: gemcitabine  cisplatin. c CT: paclitaxel  carboplatin. d Number of patients enrolled.
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(7% to 8%) also occurred in INTACT 19, and dehydration
(3% to 10%), neuropathy (4% to 6%), and alopecia (2% to
5%) occurred in INTACT 2.10
In INTACT 2, grade 3 or 4 infectious events were
significantly more frequent in the gefitinib treatment arms
(500 mg versus placebo, p  0.0099; 250 mg versus placebo,
p  0.022).10 Although only seven of the 1,075 assessable
patients (1%) in INTACT 1 and 15 of the 1,025 assessable
patients (1.5%) in INTACT 2 experienced events that were
classified as interstitial lung disease (ILD). In both trials,
treatment withdrawal because of adverse events was more
frequent in the 500-mg group (23%) compared with the
250-mg group (10% to 14%) or the placebo group (8% to
11%). In INTACT 2, post hoc analyses of patients experi-
encing rash or diarrhea events detected no statistically sig-
nificant survival differences among the three treatment
groups.10
Gefitinib as Maintenance Therapy
Kelly et al.25,26 presented the results of a Southwest
Oncology Group randomized phase III trial designed to
determine whether maintenance therapy with gefitinib would
improve survival for patients with unresected stage III
NSCLC who had undergone cisplatin-etoposide chemother-
apy with concurrent thoracic radiation, followed by consoli-
dation therapy with docetaxel. They enrolled 620 patients
into the study, and patients who did not progress after
concurrent chemoradiation with consolidation therapy were
randomized to maintenance therapy with either gefitinib (250
or 500 mg per day) or placebo. The 263 non-progressing
patients were randomized, and patient characteristics were
well balanced among the treatment groups. An unplanned
interim analysis was conducted in April 2005, and the study
was subsequently closed. Overall survival from time of ran-
domization was not significantly different among the treat-
ment groups (p  0.09). Median survival for gefitinib was 19
months, compared with 29 months for placebo. Progression-
free survival from time of randomization was also not statis-
tically different (p  0.54). There were 43 deaths in the
gefitinib arm, with 74% because of disease progression, and
32 deaths in the placebo arm, with 59% from disease pro-
gression. Adverse events were not severe with gefitinib, and
rash and diarrhea were the most common grade 3 or 4
toxicities.
Second-Line or Later Treatment
One randomized phase III trial compared gefitinib with
placebo,18 and two randomized phase II trials evaluated
different doses of gefitinib.11–13 In addition, one randomized
phase II trial evaluated docetaxel in combination with ge-
fitinib,20,21 and another trial evaluated gefitinib combined
with docetaxel versus docetaxel alone.22,23
Single-Agent Gefitinib Compared with BSC or Other
Single Agent
The double-blind, randomized phase III Iressa Survival
Evaluation in Lung (ISEL) cancer trial, which compared
gefitinib 250 mg plus BSC with placebo plus BSC among
1,692 patients refractory to or intolerant of chemotherapy,
was conducted as a requirement of the accelerated approval
of gefitinib for that indication by the U.S. Food and Drug
Administration. Randomization was conducted in a 2:1 ratio
for gefitinib versus placebo. No statistically significant over-
all survival benefit was detected for gefitinib in the entire trial
population (p  0.087) or in the subgroup of patients with
adenocarcinoma (n  812; hazard ratio [HR], 0.84; 95%
confidence interval [CI], 0.68–1.03; p  0.089). A survival
benefit in favor of gefitinib was observed among the 22% of
patients who had never smoked (HR, 0.67; 95% 0.49–0.92;
p  0.012) and the 20% of Asian origin (HR, 0.66; 95% CI,
0.48–0.91; p  0.01). Response rate for gefitinib was 8%,
compared with 1% for placebo (p  0.0001). QOL was not
statistically different between the groups (p  0.068). A
statistically significant benefit in favor of gefitinib was ob-
served for improvement in symptom score (p  0.019). Rash
and diarrhea were the most common adverse events with
gefitinib. Grade 3–4 toxicities occurred with similar inci-
dence for gefitinib and placebo, and the frequency of ILD-
like events was also similar between the groups (1%).18
The Second-line Indication of Gefitinib in NSCLC
randomized phase II trial assigned 141 patients to docetaxel
or gefitinib (250 mg daily) as second-line therapy.20,21 Pre-
liminary results of the trial were presented at ASCO 2005.
Symptom improvement rates were 36.8% and 26.0% of
patients with gefitinib and docetaxel, respectively. The re-
sponse rate for gefitinib was comparable to that for docetaxel
(13.2% versus 13.7%). Median survival was also similar for
the two arms, at 7.5 months for gefitinib and 7.1 months for
docetaxel (HR 0.97; 95% CI 0.61–1.52; p  0.88). Similar
QOL improvement rates and changes in mean QOL score
were seen for both treatments. Grade 3 or 4 hematologic
toxicities were more frequent in the docetaxel arm, although
non-hematologic toxicities occurred with similar incidence in
both arms.
Gefitinib: Dose Comparisons
Two large, fully published, randomized phase II trials
(Iressa Dose Evaluation in Advanced Lung cancer; IDEAL 1
and 2), treated patients with gefitinib for relapsed or recurrent
NSCLC.11–13 In each of the two multicenter trials, more than
200 previously treated patients were randomized to receive
oral gefitinib as monotherapy at a dose of 250 mg or 500 mg
per day.11,12 In IDEAL 1, treatment was continued until
disease progression unless consent was withdrawn, unaccept-
able toxicity occurred, or the trial closed (4 months after the
last patient was randomized).11 However, patients without
disease progression could continue treatment with gefitinib in
another study (treatment protocol not described). Palliative
radiotherapy was also allowed for isolated symptomatic bone
metastases. The number of prior chemotherapy regimens
received by patients differed between the two trials: a max-
imum of two in IDEAL 1, at least one of which was
platinum-based,11 and a minimum of two in IDEAL 2 with
previous regimens containing platinum and docetaxel given
concurrently or sequentially.12 The latter trial also required
patients to be symptomatic, defined as a score of 24 or less of
a maximum of 28 on the LCS. Most patients in both trials had
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adenocarcinoma (66% in each trial), metastatic disease (81%
to 89%), and a good PS (0–1; 80% to 87%).12
Survival and Tumor Response
Objective tumor response rates and survival were sim-
ilar for the two doses of gefitinib in both trials, with most
responses occurring within 4 weeks (68% of responders in
IDEAL 1 and 73% of responders in IDEAL 2).11,29 In IDEAL
1, a lower rate of response was assessed by an independent
blinded committee that evaluated investigator-rated partial
responses or stable disease (partial response, n  34 versus
n  38; stable disease, n  53 versus n  69). In the same
trial, objective response rates were reported to be similar for
gefitinib used as second-line (17.5% to 18.3%) or third-line
(19.6% to 20.0%) treatment.11
In a multivariate logistic regression analysis exploring
the relationship between baseline characteristics and tumor
response in IDEAL 1, a significant positive association was
detected for three of 22 potential factors: female sex (p 
0.017), tumor histology of adenocarcinoma versus other
(p  0.021), and previous immuno/hormonal treatment (p 
0.011).11 In IDEAL 2, a multivariate analysis identified fe-
male sex as the only factor associated with tumor response
(19% for women and 3% for men; p  0.001).12 The other
factors included in that analysis were PS, age, number of
prior chemotherapy regimens, months from initial diagnosis,
and tumor histology. However, in the retrospective explor-
atory subgroup analyses of IDEAL 2 reported by Cohen et
al.,30 higher response rates were also observed for nonsmok-
ers compared with smokers (29.4% versus 4.6%) in the subset
of 142 patients considered refractory or intolerant to both a
platinum agent and docetaxel.
Symptom Control and Quality of Life
In both IDEAL trials, symptoms were assessed weekly
using the LCS, and a response was defined as an improve-
ment from baseline of two or more points of a total of 28
sustained for at least 4 weeks.11,12 The full FACT-L was
completed every 28 days. Missing data can bias the results or
reduce the power of a QOL analysis.31 In both trials, missing
data points were assessed as “no symptom change.”11,13
In IDEAL 1, the median time-to-symptom improve-
ment for the 140 symptomatic patients was 8 days (the time
of the first post-baseline assessment), and improvement rates
were comparable for both treatment groups. Tumor and
symptom response seemed to be related, although that asso-
ciation was more evident in the 500-mg treatment group, with
symptom response occurring in 86% of patients with a tumor
response, 40% of patients with stable disease, and 15% of
patients with progressive disease. In patients receiving 250
mg gefitinib, the symptom improvement rates were compa-
rable among patients with tumor response (69%) or stable
disease (70%) but lower in patients with progressive disease
(12%). It was unclear whether factors other than gefitinib
administration, such as concomitant medications, could have
contributed to symptom response. Improvements from base-
line in overall QOL, as measured by the FACT-L, occurred in
24% and 22% of patients receiving 250 and 500 mg gefitinib,
respectively.
In IDEAL 2, compliance rates on the LCS and FACT-L
questionnaires were reported as 82% to 86% and 84% to
88%, respectively.13 Symptom response rates were higher in
the 250-mg gefitinib group, with most responses occurring
within 1 week of treatment initiation (56% of responding
patients).12,13 An improvement from baseline in the QOL (full
FACT-L scores) occurred with both 250 mg gefitinib (34% of
patients) and 500 mg gefitinib (23% of patients).13 In pre-
planned analyses, a positive association was reported be-
tween symptom improvement and tumor response (p 
0.001).12
Toxicity
Adverse effects were generally mild but more common
with the 500-mg gefitinib dose in both IDEAL trials, partic-
ularly for rash and diarrhea.11,12 In most cases, skin disorders
resolved during treatment or after a temporary or permanent
withdrawal from treatment. Other reported grade 1 or 2
adverse effects included dry skin (IDEAL 1, 27% [250
mg/day], 29% [500 mg/day]), vomiting (IDEAL 1, 6% [250
mg/day], 20% [500 mg/day]), nausea (IDEAL 2, 25% over-
all), and ophthalmic events (IDEAL 1, 21% overall; IDEAL
2, 19% overall). In IDEAL 2, pulmonary events occurred in
12% to 13% of patients (grade 3 or 4, 6% to 7%) but were not
considered drug-related. In one of the two patients with ILD
events in IDEAL 1, pneumonitis continued for 5 weeks until
death occurred because of disease progression.11 Although no
ILD events were reported in IDEAL 2, one possible treat-
ment-related death occurred on day 11 after a massive he-
moptysis.12 The higher dose of gefitinib was associated with
a higher rate of drug-related treatment withdrawals (IDEAL
1, 9% versus 2%; IDEAL 2, 4% versus 1%), interruptions
(IDEAL 1, 28% versus 16%), and dose reductions (IDEAL 1,
10% versus 0%; IDEAL 2, 9% versus 1%).11,12
Gefitinib-Based Combination Regimens
A trial by the Groupe Franc¸ais de Pneumo-Cance´rolo-
gie assigned patients to a combination of docetaxel plus
gefitinib at 250 mg daily versus docetaxel alone as second-
line treatment.22,23 Response rate was 19.4% for docetaxel
plus gefitinib and 10.5% for docetaxel alone. Grade 3 or 4
hematologic toxicities occurred more frequently with the
combination treatment, whereas non-hematologic toxicities
were rare in either arm. Survival and QOL analyses have yet
to be reported.
Erlotinib
Three randomized phase III trials,14–17,24,32 including
one reported in abstract form,24 have used erlotinib as treat-
ment for advanced, recurrent, or relapsed NSCLC. All trials
were placebo-controlled, with survival as the primary out-
come. Two of those trials stratified their randomization ac-
cording to disease stage,14 prior weight loss (5% in 6
months),14 presence of measurable disease,14 PS,16 prior re-
sponse to chemotherapy,16 prior number of chemotherapy
regimens,16 prior use of a platinum chemotherapy agent,16
and study center.14,16 The same two trials described how the
required sample size was estimated and met their target recruit-
ment.14,16 All three trials were sponsored by or reported an
association with a pharmaceutical company.14–17,24,32
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First-Line Treatment
Two multicenter trials (Tarceva in Lung Cancer
[TALENT] and Tarceva responses in conjunction with pac-
litaxel and carboplatin [TRIBUTE]) randomized more than
1,000 patients with good PS to receive chemotherapy with or
without erlotinib as a first-line treatment for advanced
NSCLC.14,15,24 Erlotinib was administered concurrently with
chemotherapy (gemcitabine with cisplatin in TALENT and
paclitaxel with carboplatin in TRIBUTE) and then was con-
tinued as a maintenance treatment.
Survival and Tumor Response
Neither trial detected an advantage for survival or
time-to-disease progression with the addition of erlotinib.
Similarly, time-to-symptom progression did not differ signif-
icantly between treatments in the TALENT trial,24 and tumor
response rates did not differ significantly in the TRIBUTE
trial.14 For the 116 patients in the TRIBUTE trial who had
never smoked, prolonged survival (median, 22.5 versus 10.1
months; p  0.01) and time-to-disease progression (median,
6.0 versus 4.3 months; p 0.002) were associated with
erlotinib compared with placebo treatment.14 Within the pla-
cebo group, median survival was comparable for never-smokers
and current or former smokers (10 months).14 Among the other
subgroup analyses conducted for TRIBUTE, no variables pre-
dicted overall survival.14
Eberhard et al.15 reported an analysis of EGFR muta-
tions for 228 patients in the TRIBUTE trial. In patients
receiving chemotherapy plus erlotinib, the presence of an
EGFR mutation was associated with a higher tumor response
rate (53% versus 18%; p  0.01), similar stable disease rates
(33% versus 30%), and lower rates of progressive disease
(13% versus 52%).15 EGFR mutations did not have a signif-
icant impact on tumor response for patients receiving chemo-
therapy plus placebo. The 29 patients (13%) with EGFR
mutations had longer overall survival and time-to-disease
progression than the 198 patients without mutations (p 
0.001), suggesting that the presence of an EGFR mutation is
a prognostic variable. Because no statistically significant
differences were observed by treatment group, an EGFR
mutation is not a predictive factor for survival benefit from
erlotinib, although it seems to be a predictive factor for
response.
Toxicity
In TRIBUTE, adverse events were comparable between
the treatment and control groups, except for rash and diar-
rhea. Drug-related serious adverse events (8.6% erlotinib,
2.4% placebo), severe ILD-like events (1.0% erlotinib, 0.2%
placebo), and deaths from adverse events (10.2% erlotinib,
4.4% placebo) were higher in the erlotinib arm.14 In
TALENT, grade 3 or 4 skin rash (10% versus 1%) and
diarrhea (6% versus 1%) were more common in the erlo-
tinib treatment arm.24 Other toxicities were not significantly
different.
Second-Line or Later Treatment
Shepherd et al.16 reported the results of a National
Cancer Institute of Canada Clinical Trials Group double-
blind trial of erlotinib 150 mg as monotherapy for relapsed
or recurrent NSCLC (BR 21). Randomization was con-
ducted in a 2:1 ratio for erlotinib versus placebo. A total of
731 patients were randomized. Patients were not eligible
for further chemotherapy. Most patients had a good PS
(0–1; 67%), and the treatment groups were well balanced
for patient characteristics.
Survival and Tumor Response
The overall response rate to erlotinib was 9%. In the
intent-to-treat analysis, a statistically and clinically signifi-
cant overall survival benefit was detected for erlotinib over
placebo (median, 6.7 versus 4.7 months; HR 0.70; p 
0.001). A similar benefit was detected for progression-free
survival (median, 2.2 versus 1.8 months; HR 0.61; p 0.001)
and symptom control. Various exploratory subgroup analyses
were performed to adjust for treatment effect and to identify
prognostic factors for survival. For patients treated with
erlotinib, response rates were higher among women versus
men (p  0.006), non-smokers versus current or former
smokers (p  0.001), Asians versus other ethnicities (p 
0.02), and adenocarcinoma versus other tumor histology (p
0.001).17 In a multivariate analysis, factors associated with
longer survival included treatment with erlotinib (p 0.002),
Asian ethnicity (p  0.01), adenocarcinoma (p  0.004), and
non-smoking history (p  0.048). The survival advantage of
erlotinib versus placebo was differentially affected only by
smoking history. Although erlotinib showed a benefit in most
subgroups, the sample sizes were small and may have had
inadequate power to detect a difference.
The BR.21 trial analyzed tissue samples from 328 of
731 enrolled patients to characterize the relationship between
EGFR status and outcomes. Samples were available for
mutational analysis from 177 patients. Responses to erlotinib
were higher for patients with EGFR mutations compared with
patients without mutations (16% versus 7%); however, that
difference was not statistically significant (p  0.37).17 The
survival benefit in patients treated with erlotinib versus pla-
cebo was similar among patients with EGFR mutations (HR
0.77; 95% CI, 0.40–1.50) and those who had wild type EGFR
(HR 0.73; 95% CI, 0.49–1.10).
Analyses for EGFR protein expression assessed by
immunohistochemistry (325 patients) and EGFR gene copy
number assessed by fluorescence in situ hybridization (125
patients) were also performed. The response rate to erlotinib
was higher among patients whose tumors had EGFR expres-
sion (11% versus 4%; p  0.1) and was significantly higher
for patients with an increased EGFR gene copy number (20%
versus 2%; p  0.03). Survival was greater among patients
who received erlotinib when their tumors expressed EGFR
(HR 0.68; p 0.02) than among those who did not (HR 0.93;
p  0.70) and among patients with high EGFR gene copy
number (HR 0.44; p  0.008) compared with those with low
gene copy number (HR 0.85; p  0.59). However, it must be
recognized that those subset analyses were not powered to
detect an interaction, and they detected no significant inter-
actions with respect to protein expression (p  0.25), gene
copy number (p  0.10), or mutational status (p  0.97).
Therefore, at this time, there are insufficient data to indicate
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that EGFR inhibitor therapy should be restricted to a specific
subset of patients identified by one or a combination of EGFR
tests.
Quality of Life
The QOL analysis reported for the BR.21 trial indicated
a significant benefit for erlotinib in terms of time to deterio-
ration in several patient-reported symptoms, including cough
(adjusted p  0.04), dyspnea (adjusted p  0.03), and pain
(adjusted p  0.04).16 Treatment with erlotinib was also
associated with more frequent improvement in overall phys-
ical function (p  0.01) and global QOL (p  0.01) com-
pared with placebo.32
Toxicity
Grade 3 to 5 toxicities occurred with similar incidence
in both treatment arms, with the exception of rash and
diarrhea, which occurred more frequently with erlotinib, and
infection, which occurred more frequently with placebo.
Grade 3 to 5 pneumonitis occurred in1% of patients in both
arms.16
DISCUSSION
The two INTACT trials and the TALENT and TRIBUTE
trials demonstrate that combining gefitinib or erlotinib with
platinum-based chemotherapy in the way that it was used in
those trials was not beneficial as first-line treatment in ad-
vanced NSCLC.9,10,14,15,24 The Southwest Oncology Group
trial demonstrates that gefitinib is not beneficial as mainte-
nance therapy after concurrent chemoradiation with consoli-
dation therapy in patients with unresected stage III
NSCLC.25,26 Data on the use of gefitinib or erlotinib as
first-line monotherapy for advanced NSCLC are limited to
preliminary reports from small single-arm trials.34–48
The data from the IDEAL trials suggest that gefitinib
may be of use in selected symptomatic patients with ad-
vanced NSCLC who are appropriate for third-line therapy
(i.e., those with relapsed or recurring disease after two lines
of chemotherapy and a reasonable PS, 0–2), based on tumor
and symptom response rates.11–13 However, the ISEL trial did
not show a statistically significant survival benefit for ge-
fitinib compared with placebo in patients refractory to, or
intolerant of, prior chemotherapy, although a benefit was
observed in subgroups of patients who had never smoked or
were of Asian ethnicity.18 The evidence from one large,
randomized placebo-controlled trial (BR.21) demonstrates
that erlotinib monotherapy is an effective treatment for pa-
tients with advanced NSCLC that has relapsed or recurred
after prior chemotherapy and who are not eligible for further
chemotherapy. Statistically and clinically significant im-
provements in progression-free and overall survival and time-
to-symptom deterioration were detected with the administra-
tion of erlotinib compared with placebo.16 It is not clear why
a significant survival benefit was seen in BR.21 and not in the
ISEL trial. It has been postulated that the 250-mg dose of
gefitinib may have been too low, although the results of the
IDEAL 1 and 2 trials would argue against that explanation,
given the similarity in response rate and survival end points
for gefitinib 250 mg/day and 500 mg/day.11–13 Both the
BR.21 and the ISEL trial included patients who were ineli-
gible for further chemotherapy; however, patients in the ISEL
trial were also required to be intolerant of or have progressed
within 90 days after their most recent chemotherapy regimen.
Also, approximately 39% of the patients in the ISEL trial had
progressive disease as their best response to previous chemo-
therapy, compared with 28% for BR.21.16,18 It is possible that
this difference in baseline patient characteristics may explain
some of the difference in results.
Although overall response rates for gefitinib and erlo-
tinib in relapsed or recurrent NSCLC are modest, exploratory
analyses suggest that some patient subgroups (e.g., wom-
en,11,12 Asians,16 patients with adenocarcinoma tumor histol-
ogy,11 patients who have never smoked,49 and those with
EGFR mutations15,50–52) may be more likely to achieve ob-
jective response to those agents. The incidence of EGFR
mutations is significantly greater in patients with adenocar-
cinoma, non-smokers, and women.51,53 However, in the ab-
sence of a comparative treatment or placebo control group, it
is difficult to determine whether differences in treatment
outcome by subgroup are a result of prognostic factors
inherent to the subgroups or of a differential treatment inter-
action with the subgroup. The exploratory analyses of sur-
vival in the placebo-controlled BR.21 trial of erlotinib sug-
gest that almost all patient subgroups have the potential to
derive a survival benefit.16 To date, research on EGFR mu-
tations has been limited mainly to retrospective analyses of
subsets of patients for whom genetic samples are available.
The analysis of the TRIBUTE trial showed that the 29
patients with EGFR mutations had longer overall survival and
time-to-disease progression than the 198 patients without
mutations (p  0.001) regardless of the type of treatment;
however, no statistically significant differential effect was
observed between the erlotinib and placebo-treated groups.15
In the BR.21 trial, no statistically significant benefit in re-
sponse was observed for patients with EGFR mutations
compared with those without mutations, and the survival
benefit of erlotinib versus placebo was similar among patients
with and without EGFR mutations.17 Those results suggest
that, at this time, mutation analysis is not required to select
patients for treatment with erlotinib in this setting; however,
the number of patients evaluated was small.
The toxicity data for gefitinib suggest it is quite well
tolerated, with generally mild, dose-dependent adverse ef-
fects mostly related to skin disorders and diarrhea. In the two
IDEAL trials, skin rashes typically resolved during treatment
or after the temporary or permanent withdrawal of gefitinib.
Nausea, vomiting, elevated transaminase levels, and ophthal-
mic disorders have also been reported with varying fre-
quency. The incidence of ILD-type events ranged from 0% to
2% in randomized trials9–12 and was comparable for chemo-
therapy combined with either gefitinib or placebo.9,10 The
U.S. Food and Drug Administration label indicates that ILD
in patients receiving gefitinib has an overall incidence of
approximately 1% to date, with approximately 33% of oc-
currences being fatal.54 The label warns that gefitinib should
be interrupted or discontinued when pulmonary symptoms
worsen or occur suddenly. The administration of erlotinib is
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associated with toxicities similar to those of gefitinib, with
diarrhea and skin disorders being the most commonly re-
ported events. In TRIBUTE, the incidence of severe ILD-type
events was 1% in the erlotinib arm and 0.2% in the placebo
arm.14 Grade 3 or 4 pneumonitis or pulmonary events have
also been reported in small trials.46,55
CONCLUSIONS
There is strong evidence to recommend against the use
of gefitinib or erlotinib in combination with standard cispla-
tin-based first-line chemotherapy or as maintenance therapy
after first-line treatment for advanced NSCLC.9,10,14,24–26 In
the second-line or later treatment setting, two randomized,
placebo-controlled, phase III trials evaluated the use of ge-
fitinib or erlotinib as a treatment in NSCLC. Data suggest that
these agents may have a clinically beneficial treatment effect,
especially given the lack of other available treatment options
in this setting.
Erlotinib monotherapy in the second-line or later set-
ting can be recommended for patients who are not candidates
for further chemotherapy based on the improved survival,
tumor response, symptom control, and QOL observed when
erlotinib was compared with placebo in a large, randomized,
controlled trial.16 In addition, the toxicity associated with the
administration of erlotinib was minimal.
A large, randomized trial did not demonstrate a statis-
tically significant survival benefit for gefitinib compared with
placebo in patients with relapsed or recurrent NSCLC.18
However, the evidence from two randomized phase II trials
suggests that rapid symptomatic relief can be obtained for
patients receiving gefitinib monotherapy as third-line treat-
ment.11,12 Although these trials did not include a placebo
comparison group, the rapid symptom response (typically
within 2 weeks) and the fact that the symptom response was
associated with an objective response suggests that symptom
benefit could be attributed to the administration of gefitinib.
In addition, a large number of patients treated with gefitinib
have shown stable disease, and that is a positive outcome
regardless of whether symptom improvement occurs.
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